EXPLORING THE POSSIBLE MECHANISM OF ALBIZIA LEBBECK COMPONENTS BINDING WITH DRUG TARGETS OF BRONCHIAL ASTHMA –AN INSILICO AND CLINICAL ANALYSIS

Asthma is a multi factorial disease characterized by airflow obstruction, wheezing and dysonea and for this many genes are responsible. In this study, an attempt has been made to identify genes along with the proteins encoded by them which are responsible for Asthma along with clinical trials. In the practice of Ayurveda, it’s well established that shirish (Albizia lebbeck) can be used as a treatment of Asthma. However, how the compounds of shirish bark functions at the molecular level is yet unknown. The present study shows an insilico molecular interaction studies and clinical trials as well for the compounds of shirish bark. The results show how the compounds of shirish bark affect the target proteins of asthma which actually will aid in the design of putative inhibitor. Among the screened 9 (nine) compounds of shirish, all the compounds are giving good binding affinity to the selected proteins and among them lebbecacidin interacts potentially and is also showing lowest binding energy with IL-5, one of the target proteins. Lebbecacidin has satisfied all the criteria for a potential lead with drug likeliness 1.26, drug score 0.83, high solubility and high cell membrane permeability and it has also been calculated to be non toxic which was also validated by clinical studies.